Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

F
Fabbri, Nicole

Dipartimento di Medicina Molecolare, Università di Pavia
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Nicole Fabbri
Favorite
Facchinelli, Davide

Ospedale San Bortolo
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Davide Facchinelli
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Davide Facchinelli
Favorite
Facco, Monica

University of Padua
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Monica Facco
Favorite
Faitova, Tereza

Rigshospitalet, Copenhagen University Hospital
1053 - Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
Tereza Faitova
Favorite
Fakhri, Bita

University of California San Francisco
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Bita Fakhri
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Bita Fakhri
Favorite
Fam, Fady

AstraZeneca
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Fady Fam
Favorite
Fan, Lei

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Lei Fan
Favorite
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Lei Fan
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Lei Fan
Favorite
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Lei Fan
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Lei Fan
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Lei Fan
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Lei Fan
Favorite
Farber, Charles M.

Atlantic Hematology Oncology, Carol G. Simon Cancer Center
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Charles M. Farber
Favorite
Fardoun, Rayan

Dana-Farber Cancer Institute
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Rayan Fardoun
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Rayan Fardoun
Favorite
Faria Zeni, Pedro

CEITEC MU
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Pedro Faria Zeni
Favorite
Farina, Giuliana

13. Hematology and Medical Oncology, AORN Sant’Anna e San Sebastiano
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Giuliana Farina
Favorite
Farina, Lucia

Fondazione IRCCS Istituto Nazionale dei Tumori
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Lucia Farina
Favorite
Farooqui, Mohammed

Merck & Co., Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Mohammed Farooqui
Favorite
Favale, Nicolás
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Nicolás Favale
Favorite
Fayard, Amandine

CHU Clermont-Ferrand
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Amandine Fayard
Favorite
Fayault, Alexandra
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Alexandra Fayault
Favorite
Fazzi, Rita

Azienda Ospedaliera Universitaria Pisana
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Rita Fazzi
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Rita Fazzi
Favorite
Fegan, Christopher

Division of Cancer and Genetics, School of Medicine, Cardiff University
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Christopher Fegan
Favorite
Feldman, Tatyana

John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Tatyana Feldman
Favorite
Feng, Ru

Department of Hematology, Nanfang Hospital, Southern Medical University
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Ru Feng
Favorite
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Ru Feng
Favorite
Fenwick, Lynsey

IQVIA
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Lynsey Fenwick
Favorite
Fernandes, Laura L.

COTA, Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Laura L. Fernandes
Favorite
Fernandes, Pedro

Division of Hematology, UNIFESP
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Pedro Fernandes
Favorite
Fernandes, Stacey

Dana-Farber Cancer Institute
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Stacey Fernandes
Favorite
1031 - Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Stacey Fernandes
Favorite
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Stacey Fernandes
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Stacey Fernandes
Favorite
Fernandez, Gabriel
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Gabriel Fernandez
Favorite
Ferrà, Christelle

Institut Català d'Oncologia-Hospital Germans Trias i Pujol
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Christelle Ferrà
Favorite
Ferrajoli, Alessandra

UT MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Alessandra Ferrajoli
Favorite
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Alessandra Ferrajoli
Favorite
Ferrant, Emmanuelle

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Emmanuelle Ferrant
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Emmanuelle Ferrant
Favorite
Ferrario, Andrea

ASST dei Sette Laghi-Ospedale di Circolo di Varese
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Andrea Ferrario
Favorite
Feugier, Pierre

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France Department of Hematology, University Hospital of Nancy, Vandoeuvre-lès-Nancy
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Pierre Feugier
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Pierre Feugier
Favorite
Filip, Daniel

CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Daniel Filip
Favorite
Fink, Anna

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Anna Fink
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Anna Fink
Favorite
Fischer, Kirsten

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Kirsten Fischer
Favorite
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Kirsten Fischer
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Kirsten Fischer
Favorite
Fisch, Michael

AIM Specialty Health
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Michael Fisch
Favorite
Fitch, Mark

Department of Nutritional Sciences & Toxicology, University of California at Berkeley
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Mark Fitch
Favorite
Flaherty, Kelsey

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Kelsey Flaherty
Favorite
Fleury, Isabelle

Hôpital Maisonneuve-Rosemont, University of Montreal
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Isabelle Fleury
Favorite
Flinn, Ian

Sarah Cannon Research Institute/Tennessee Oncology
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Ian Flinn
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Ian Flinn
Favorite
Flochová, Emília

Department of Hematology and Transfusion, University Hospital Martin
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Emília Flochová
Favorite
Floerchinger, Alessia

German Cancer Research Center (DKFZ) Heidelberg
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Alessia Floerchinger
Favorite
Foà, Robin

Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Robin Foà
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Robin Foà
Favorite
Follit, Courtney

Biomea Fusion
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Courtney Follit
Favorite
Font, Patricia

Hospital General Universitario Gregorio Marañon
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Patricia Font
Favorite
Forconi, Francesco

Cancer Sciences, Faculty of Medicine, University of Southampton
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Francesco Forconi
Favorite
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Francesco Forconi
Favorite
Forestieri, Gabriela

Laboratory of Experimental Hematology, Institute of Oncology Research
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Gabriela Forestieri
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Gabriela Forestieri
Favorite
Forsyth, Cecily

Gosford Hospital
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Cecily Forsyth
Favorite
Fox, Christopher P.

Department of Clinical Haematology, Nottingham University Hospitals NHS Trust
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Christopher P. Fox
Favorite
Fox, Sonia

Institute of Cancer and Genomic Sciences, University of Birmingham
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Sonia Fox
Favorite
Frawley, Thomas

Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre
1150 - Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)
Thomas Frawley
Favorite
Freeman, Jane
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Jane Freeman
Favorite
Freestone, Clare

Oncology Clinical Trials Office
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Clare Freestone
Favorite
Frenquelli, Michela

IRCCS Ospedale San Raffaele
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Michela Frenquelli
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Michela Frenquelli
Favorite
Fresa, Alberto

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Alberto Fresa
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Alberto Fresa
Favorite
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Alberto Fresa
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Alberto Fresa
Favorite
Frezzato, Federica

University of Padua
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Federica Frezzato
Favorite
Frigola, Gerard

Hospital Clínic de Barcelona
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Gerard Frigola
Favorite
Fufulan, Amro

Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Amro Fufulan
Favorite
Fu, Lei

Ascentage Pharma Group Inc.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Lei Fu
Favorite
Furman, Richard

Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Richard Furman
Favorite
Fu, Zheng

MegaRobo Technologies Co., Ltd, Suzhou
1014 - Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome
Zheng Fu
Favorite